Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

Summary: Background: We previously demonstrated the safety and immunogenicity of an MF59-adjuvanted COVID-19 vaccine based on the SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a molecular clamp using HIV-1 glycoprotein 41 sequences. Here, we describe 12-month results in a...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Keith J. Chappell, Francesca L. Mordant, Alberto A. Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet, Luca Hensen, Wuji Zhang, Thi H.O. Nguyen, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Katherine Kedzierska, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro
التنسيق: مقال
اللغة:English
منشور في: Elsevier 2023-11-01
سلاسل:EBioMedicine
الموضوعات:
Clinical trial
Phase 1
COVID-19 vaccine
Severe acute respiratory syndrome coronavirus 2
Spike protein
SARS-CoV-2
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S2352396423004085

الانترنت

http://www.sciencedirect.com/science/article/pii/S2352396423004085

مواد مشابهة